IGS1 Stock Overview
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IGC Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.45 |
| 52 Week High | US$0.69 |
| 52 Week Low | US$0.23 |
| Beta | 1.77 |
| 1 Month Change | 47.06% |
| 3 Month Change | 89.08% |
| 1 Year Change | 47.06% |
| 3 Year Change | -65.12% |
| 5 Year Change | -68.77% |
| Change since IPO | -95.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| IGS1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 11.4% | -3.1% | -2.0% |
| 1Y | 47.1% | -31.9% | -0.3% |
Return vs Industry: IGS1 exceeded the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: IGS1 exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| IGS1 volatility | |
|---|---|
| IGS1 Average Weekly Movement | 19.0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IGS1's share price has been volatile over the past 3 months.
Volatility Over Time: IGS1's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 61 | Ram Mukunda | igcpharma.com |
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps.
IGC Pharma, Inc. Fundamentals Summary
| IGS1 fundamental statistics | |
|---|---|
| Market cap | €30.39m |
| Earnings (TTM) | -€13.28m |
| Revenue (TTM) | €1.14m |
24.2x
P/S Ratio-2.1x
P/E RatioIs IGS1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGS1 income statement (TTM) | |
|---|---|
| Revenue | US$1.22m |
| Cost of Revenue | US$591.00k |
| Gross Profit | US$625.00k |
| Other Expenses | US$14.77m |
| Earnings | -US$14.14m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 51.40% |
| Net Profit Margin | -1,163.24% |
| Debt/Equity Ratio | 1.6% |
How did IGS1 perform over the long term?
See historical performance and comparison